Skip to main content

Table 1 General study characteristics of the models evaluating routine varicella vaccination

From: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Study

Country

Model type

Accounting for herd protection

Impact of varicella vaccination on HZ incidence

Time horizon

Type of economic evaluation

Perspective

Discount rate (costs/health effects)

Costing year and currency

Funding source

Banz et al. [35]

Germany

Dynamic

Yes

No

30 years

CC

Health care payer; societal

5 %/0 %

1999 EUR

Industry

Banz et al. [51]

Switzerland

Dynamic

Yes

No

30 years

CC; CEA

Health care payer; societal

5 %/0 %

2008 CHF

Industry

Beutels et al. [37]

Germany

Static

No

No

70 years

CC; CEA

Health care payer; societal

5 %/5 %

1995 DEM

Independent

Bilcke et al. [30]

Belgium

Dynamic

Yes

Depending on the type of analysis

Various

CEA; CUA

Health care payer

3 %/1.5 %

2010a EUR

Independent

Bonanni et al. [36]

Italy

Dynamic

Yes

No

30 years

CC

Health care payer; societal

3 %/0 %

2007a EUR

Industry

Brisson et al. [31]

Canada

Dynamic

Yes

Yes (only in a separate analysis)

30 years

CC; CEA

Health care payer; societal

3 %/3 %

1997/1998 CAD

Independent

Brisson et al. [32]

England and Wales

Dynamic

Yes

Yes

80 years

CUA

Health care payer; societal

3 %/3 %

2001 GBP

Independent

Coudeville et al. [52]

France

Dynamic

Yes

No

30 years

CC

Health care payer; societalb

5 %/NA

1995 FRF

Industry

Coudeville et al. [53]

Italy

Dynamic

Yes

No

50 years

CC

Health care payer; societal

3 %/NA

2002 EUR

Industry

Coudeville et al. [54]

France and Germany

Dynamic

Yes

No

50 years

CC; CEA

Health care payer; societal

3 %/3 %

2002 EUR

Industry

Diez Domingo et al. [55]

Spain

Static

No

No

20 years

CC

Health care payer; societal

5 %/NA

1994 PTA

Independent

Getsios et al. [56]

Canada

Static

No

No

70 years

CEA; CUA

Health care payer; societal

3 %/3 %

1998 CAD

Independent

Ginsberg & Somekh [57]

Israel

Static

Partially

No

Lifetime

CC

Health care payer; societal

3 %/NA

2002 USD

Independent

Hammerschmidt et al. [58]

Germany

Dynamic

Yes

No

30 years

CC

Health care payer; societal

Not specified (probably 5 % for costs)

1999/2006c EUR

Industry

Huse et al. [59]

USA

Static

No

No

24 years

CC

Societal

5 %/5 %

1991 USD

Industry

Lenne et al. [60]

Spain

Dynamic

Yes

No

50 years

CC; CEA

Health care payer; societal

3 %/0 %

2004 EUR

Industry

Lieu et al. [61]

USA

Dynamic

Yes

No

30 years

CC; CEA

Health care payer; societal

5 %/5 %

1990 USD

Independent

Preblud et al. [62]

USA

Static

No

No

30 years

CC

Health care payer; societal

5 %/0 %

1984 USD

Independent

Scuffham et al. [63]

New Zealand

Static

No

No

30 years

CC

Health care payer; societal

5 %/5 %

1997 NZD

Industry

Scuffham et al. [34]

Australia

Static

No

No

30 years

CEA

Health care payer

5 %/5 %

1996/1997 AUD

Independent

Thiry et al. [64]

Italy

Static

No

No

100 years

CC; CEA

Health care payer; societal

3 %/3 %

2002 EUR

Industry

van Hoek et al. [33]

UK

Dynamic

Yes

Yes

Infinite

CUA

Health care payer

3.5 %/3.5 %

2007 GBP

Independent

Zhou et al. [29]

USA

Static

No

No

Lifetime

CC; CUA

Health care payer; societal

3 %/3 %

2006 USD

Industry

  1. CC cost-comparison; CEA cost-effectiveness analysis; CUA cost-utility analysis; NA = not applicable
  2. aAssumption
  3. bIndirect costs were not evaluated in monetary terms but reported as the number of days of absence from work
  4. cPersonal communication with the author (1999 prices; 2006 vaccine prices)